Nitazoxanide
Nitazoxanide (nitazoxanide) is a small molecule pharmaceutical. Nitazoxanide was first approved as Alinia on 2002-11-22. It is used to treat cryptosporidiosis, diarrhea, giardiasis, and protozoan infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Nitazoxanide (discontinued: Alinia)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitazoxanide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALINIA | Romark Laboratories L.c. | N-021497 DISCN | 2004-07-21 | 1 products, RLD |
| ALINIA | Romark Laboratories L.c. | N-021498 DISCN | 2002-11-22 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alinia | New Drug Application | 2024-03-20 |
| nitazoxanide | ANDA | 2022-03-31 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | 1 | 19 | 16 | 2 | 1 | 30 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 2 | 11 | 3 | 2 | — | 14 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 10 | 3 | 2 | — | 13 |
| Hepatitis c | D006526 | — | B19.2 | 2 | 10 | 3 | 2 | — | 13 |
| Infections | D007239 | EFO_0000544 | — | 2 | 6 | 5 | 3 | — | 11 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 7 | 2 | 2 | — | 9 |
| Communicable diseases | D003141 | — | — | 2 | 5 | 2 | 2 | — | 7 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 6 | 2 | 1 | — | 7 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | 1 | 2 | — | 5 |
| Helicobacter infections | D016481 | EFO_1000961 | — | — | — | 2 | 2 | — | 4 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 5 | 1 | — | 1 | 8 |
| Cryptosporidiosis | D003457 | — | A07.2 | 1 | 2 | 2 | — | 2 | 6 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 5 | 1 | — | — | 5 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | 2 | 4 | — | — | 5 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 2 | 2 | — | 1 | 4 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | 2 | 2 | — | 1 | 4 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 1 | 2 | 1 | — | 1 | 4 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | 1 | 2 | 2 | — | 1 | 4 |
| Gastroenteritis | D005759 | EFO_1001463 | K52.9 | — | 3 | 1 | — | — | 3 |
| Rotavirus infections | D012400 | — | — | — | 2 | 1 | — | 1 | 3 |
Show 25 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 1 | 2 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Hepatitis b | D006509 | — | — | — | 1 | — | — | — | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 1 | — | — | — | 1 |
| Coinfection | D060085 | — | — | — | 1 | — | — | — | 1 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | 1 | — | — | — | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
| Coronavirus | D017934 | — | — | — | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral palsy | D002547 | — | G80 | — | — | — | — | 2 | 2 |
| Diet therapy | D004035 | — | — | — | — | — | — | 1 | 1 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | — | 1 | 1 |
| Child nutrition disorders | D015362 | — | — | — | — | — | — | 1 | 1 |
| Probiotics | D019936 | — | — | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Muscle spasticity | D009128 | HP_0001257 | — | — | — | — | — | 1 | 1 |
| Paralysis | D010243 | HP_0003470 | — | — | — | — | — | 1 | 1 |
| Microsporidiosis | D016881 | EFO_0007366 | B60.8 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nitazoxanide |
| INN | nitazoxanide |
| Description | Acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester is a carboxylic ester and a member of benzamides. It is functionally related to a salicylamide. |
| Classification | Small molecule |
| Drug class | antiparasitics (salicylanilide derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1 |
Identifiers
| PDB | — |
| CAS-ID | 55981-09-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1401 |
| ChEBI ID | — |
| PubChem CID | 41684 |
| DrugBank | DB00507 |
| UNII ID | SOA12P041N (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nitazoxanide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,573 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
487 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use